XERS — Xeris Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1867096 ·
Last close
$8.74
Market Cap
$1.59B
52W High
$9.02
52W Low
$5.81
ADV30
1,649,378
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 92,100,000 | 79,588,000 | 5,173,000 | -31,101,000 | 411,905,000 | 121,747,000 | 421,639,000 |
| Mar 2026 | 83,127,000 | 72,553,000 | 7,916,000 | 2,234,000 | 392,013,000 | 111,750,000 | 379,002,000 |
| Dec 2025 | 85,807,000 | 74,860,000 | 16,773,000 | 11,081,000 | 383,527,000 | 111,042,000 | 369,838,000 |
| Sep 2025 | 74,380,000 | 63,384,000 | 6,731,000 | 621,000 | 370,191,000 | 91,598,000 | 371,052,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$56,608,000
Investing CF
$-938,000
Financing CF
$6,690,000
CapEx
$-938,000
Dividends Paid
—
Buybacks
$-19,226,000
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-700,174,000
Inventory
$80,930,000
Receivables
$58,105,000
ST Investments
$0
EBIT TTM
$11,087,000
Pretax Income TTM
$-17,165,000
Interest Exp TTM
$28,252,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$335,414,016
EBITDA
$48,769,000
Free Cash Flow
$52,450,124
Enterprise Value
$1,753,881,600
Total Cash
$121,747,000
Total Debt
$289,441,984
Shares Out
182,320,306
Trailing EPS
$-0.10
Book Value
$-0.06
ROE
—
ROA
6.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 291,845,000 | 24,896,000 | 554,000 | 383,527,000 | 369,838,000 | — | 28,626,000 |
| Dec 2024 | 203,070,000 | -33,646,000 | -54,836,000 | 323,060,000 | 352,675,000 | — | -36,981,000 |
| Dec 2023 | 163,914,000 | -44,010,000 | -62,255,000 | 322,602,000 | 329,384,000 | — | -47,023,000 |
| Dec 2022 | 110,248,000 | -81,940,000 | -94,660,000 | 344,522,000 | 299,335,000 | — | -102,891,000 |
TTM Snapshot
Revenues TTM
$143,373,000
NetIncome TTM
$-75,767,000
OpCashFlow TTM
$0
Assets (Latest)
$323,060,000
Forward EPS
$0.39
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $8.74 · call volume: 103 · put volume: 22
Expected Move to 2026-10-16:
±$1.99
(22.77%) —
implied range
$6.75 –
$10.73
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | $1.56B | $23.58 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.56B | $16.71 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.56B | $48.21 | — |
| FBRX | Forte Biosciences, Inc. | $1.63B | $76.95 | — |
| TYRA | Tyra Biosciences, Inc. | $1.55B | $26.09 | — |
News headlines (Yahoo Finance, 1h cache)
Xeris (XERS) Q2 2026 Earnings Call Transcript
2026-08-13 16:15 · Yahoo
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-08-06 23:13 · Yahoo
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
2026-08-06 13:30 · Yahoo
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
2026-07-08 14:37 · Yahoo
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-03 02:40 · Yahoo
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
2026-06-30 13:08 · Yahoo
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
2026-05-15 11:49 · Yahoo
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
2026-05-09 14:19 · Yahoo
Xeris Biopharma Announces Private Exchange of Convertible Notes
2026-06-11 11:00 · Yahoo
Xeris Biopharma Q1 Earnings Call Highlights
2026-05-09 08:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.